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LETTER TO THE EDITOR
Bicuspid aortic stenosis in transcatheter aortic 
valve replacement era: Emerging confusions  
hindering the standardization of the procedure
Tian-Yuan Xiong, Zhen-Gang Zhao, Mao Chen
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China
Bicuspid aortic valve (BAV) has long been 
regarded as a relative contraindication for tran-
scatheter aortic valve replacement (TAVR). The 
incidence of aortic stenosis in patients with BAV is 
high, but the onset of symptoms is usually at a rela-
tively young age. As TAVR is moving to younger 
and lower-risk patients, the proportion of patients 
with BAV will increase. Some initial off-label ex-
perience and small registries have demonstrated 
the safety and efficacy of treating bicuspid aortic 
stenosis with TAVR. Novel strategies dealing with 
BAV and devices are also emerging along the way 
aiming for better outcomes. Nevertheless, multi-
center collaborative randomized controlled trials 
are required before official approval in this field. For 
this purpose, it is time to clarify several confusions 
that hinders the standardization of the procedure 
in BAV (Table 1).
Not all BAV subtypes behave the same or are 
suitable for TAVR. However, there is no consensus 
regarding which anatomical presentation should 
be selected for the procedure. The current clas-
sification system of BAV does not satisfy the need 
for TAVR and only provides limited information 
for patient selection and prediction of outcomes. 
In a recent attempt to simplify BAV classification 
relevant to TAVR, a previously neglected mor-
phology of tricommissural (functional/acquired) 
BAV was delineated [1]. However, the proposed 
system failed to predict the rates of moderate or 
severe aortic regurgitation at discharge or the new 
permanent pacemakers at 30 days. 
Classification for BAV in the TAVR era is 
indeed difficult due to the involvement of many 
potential factors that could influence outcomes. 
A better understanding of the calcification mode 
and its behavior is required for an evaluation of 
procedural feasibility and risk in BAV. Leaflet 
length and bulkiness relative to sinus size, in ad-
dition to coronary height should be assessed, to 
better predict coronary risk. Thus, apart from the 
number of cusps and commissures and modes of 
fusions, raphe length, calcification modes and its 
distribution, leaflet length, size and asymmetry 
of sinuses may also need to be incorporated into 
a future system. 
It has been shown that new-generation valves 
reduced the rates of paravalvular leak (PVL), 
annular rupture and second valve implantation 
compared with the early-generation ones [2]. De-
spite having the PVL issue being tackled with an 
additional seal on the prosthesis, the common non-
circular shape of prosthesis frame after deployment 
observed in BAV still raises concerns for durabil-
ity/bioprosthesis degeneration when considering 
the younger ages of BAV patients being referred, 
especially with the intra-annular valve design. 
A BAV-friendly prosthesis design, takes advan-
tage of both from the current balloon-expandable 
and self-expanding devices, which could be a po-
tential solution. The proposed design should ideally 
a) have a strong radial force to circularize the native 
anatomy and avoid severe stent deformation; b) be 
supra-annular, so as to utilize the stent frame below 
the nadir of bioprosthesis as part of left ventricular 
outflow tract to achieve better geometry at the 
level of the functioning leaflets and larger effec-
tive orifice area; c) be relatively short to prevent 
radial force being exposed to possible untreated 
aortic aneurysm.
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Selection of the right prosthesis size is of 
great importance to the success of TAVR. The fact 
that perimeter- or area-derived diameters at the 
annulus are usually much larger than that of the 
exact valvar opening (typical ‘fish-mouth’ appear-
ance) in BAV [3] makes the conventional sizing 
strategy based on the annulus less appealing. Thus, 
some novel strategies appear. As a preparatory 
step, balloon aortic valvuloplasty enables a direct 
view of the specific anatomical characteristics and 
post-implant prediction [4]. However, due to the 
different shape and length of a balloon compared to 
a certain device, the prediction from balloon-sizing 
will be imperfect. Another theory is supra-annular 
sizing. The spline was determined between 4 and 
8 mm above the annulus by empirically predicting 
native cusp capacity for implanted transcatheter 
heart valve from actual valvar opening, the pres-
ence of raphes and calcifications. Similarly, there 
is the concept of inter-commissural distance, 
which was measured at 4 mm above the annulus. 
The prosthesis inter-commissural distance ratio 
was found to be smaller than the correspondent 
prosthesis annulus ratio, suggesting the level 
4 mm above the annulus had more restrictions to 
the device than the annulus. These latter two con-
cepts are still preliminary, but they define device 
landing zone besides the annulus by focusing on the 
region which theoretically restricts the implanted 
prosthesis most. 
The key to a new strategy is an accurate pre-
diction of the anchoring zone. This relies on inves-
tigations on the behavior of BAV leaflets and tran-
scatheter heart valve stent based on post-implant 
computed tomography, mechanics and flow field, and 
the development of dedicated software to predict 
the post-implant interactions of stents and leaflets.
The coexistence of an ascending aortic an-
eurysm is common among patients with bicuspid 
aortic stenosis, which would render surgery man-
datory in order to treat both lesions simultaneously. 
Isolated TAVR is unable to address aortopathy, 
which raises the potential risk of rupture or dissec-
tion. To date , there have been reports of combined 
TAVR and thoracic endovascular aneurysm repair. 
Although it could be technically challenging, 
given the trend of developing combined percuta-
neous solutions to different disease groups, there 
remains a possibility for a one-stage transcatheter 
treatment of bicuspid aortic stenosis with con-
comitant aortopathy by a single device. Benefits 
of this one-stage procedure would be a reduc-
tion in total procedural time, safe valve delivery 
(within pre-implanted aneurysm stent) and better 
adaptation to the native anatomy, but issues such 
as minimizing catheter profile, device length and 
determining ways of coronary protection etc. need 
to be resolved first.
Three years ago, there was a review of TAVR 
utilization in BAV [5]. Back then, the proportion 
Table 1. Summary of confusions that hinders the standardization of transcatheter aortic valve  
replacement (TAVR) in bicuspid aortic valve (BAV).
Confusions Importance of clarifying the problem Possible solutions
Anatomical classification Current classification system of BAV 
could not satisfy TAVR need and only 
provides limited information for patient 
selection and the prediction of outcomes
Apart from the number of cusps and 
commissures and modes of fusions,  
raphe length, calcification modes and  
its distribution, leaflet length, size and  
asymmetry of sinuses may also need  
to be incorporated into a future system
BAV-friendly  
prosthesis design
The common non-circular shape of  
implanted stent frame raises the concern 
of early bioprosthesis degeneration
Prosthesis design should ideally: a) have 
strong radial force; b) be supra-annular; 
c) be relatively short
BAV-specific prosthesis  
sizing strategy
Current sizing strategy was developed 
from tricuspid aortic valve, which does 
not fully appreciate the ‘fish-mouth’  
valvular opening often seen in BAV  
and may result in excessive oversizing
To predict the anchoring zone accurately, 
which relies on investigations on the  
behavior of BAV leaflets and transcatheter 
heart valve stent based on post-implant 
computed tomography, mechanics and 
flow field, and the development of  
dedicated software
Concomitant aortopathy Isolated TAVR is unable to address  
aortopathy, which raises the potential  
risk of rupture or dissection
One-stage transcatheter treatment  
of bicuspid aortic stenosis with  
concomitant aortopathy
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of BAV patients was extremely low in fairly large 
TAVR registries. The myth of denying BAV merely 
due to this morphology for TAVR has now been 
partially settled, yet plenty of new uncertainties are 
revealed. To be an established treatment option for 
bicuspid aortic stenosis, extensive collaborations 
between scientists, engineers (valve manufac-
turer and information technology), imaging special-
ists, and interventionists are required to develop 
a new classification system, dedicated software 
and devices for BAV.
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